Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -33,560 | -26,048 | -29,769 | -29,025 | -15,894 |
| Depreciation Amortization | 90 | 126 | 127 | 130 | 164 |
| Other Working Capital | 555 | 231 | 1,622 | 224 | 1,038 |
| Other Operating Activity | 10,180 | 1,829 | 4,429 | 1,032 | -4,259 |
| Operating Cash Flow | $-22,735 | $-23,862 | $-23,591 | $-27,639 | $-18,951 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -13 | -124 | -67 | -19 |
| Investing Cash Flow | $N/A | $-13 | $-124 | $-67 | $-19 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 27,292 | 4,661 | 4,166 | N/A | 74,747 |
| Other Financing Activity | -8 | -26 | -25 | -23 | -23 |
| Financing Cash Flow | $27,284 | $4,635 | $4,141 | $-23 | $74,724 |
| Exchange Rate Effect | 51 | -32 | -21 | -29 | -24 |
| Beginning Cash Position | 4,278 | 23,550 | 43,145 | 70,903 | 15,173 |
| End Cash Position | 8,878 | 4,278 | 23,550 | 43,145 | 70,903 |
| Net Cash Flow | $4,600 | $-19,272 | $-19,595 | $-27,758 | $55,730 |
| Free Cash Flow | |||||
| Operating Cash Flow | -22,735 | -23,862 | -23,591 | -27,639 | -18,951 |
| Capital Expenditure | N/A | -13 | -124 | -67 | -19 |
| Free Cash Flow | -22,735 | -23,875 | -23,715 | -27,706 | -18,970 |